Clarity Wealth Advisors LLC Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Clarity Wealth Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 14.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 312 shares of the company’s stock after selling 51 shares during the quarter. Clarity Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $241,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. AMF Tjanstepension AB lifted its stake in shares of Eli Lilly and Company by 113.7% in the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the period. Values Added Financial LLC raised its holdings in Eli Lilly and Company by 4.9% in the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after purchasing an additional 17 shares in the last quarter. Iowa State Bank lifted its position in Eli Lilly and Company by 8.9% during the third quarter. Iowa State Bank now owns 5,612 shares of the company’s stock valued at $4,972,000 after buying an additional 460 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Eli Lilly and Company by 52.1% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 29,176 shares of the company’s stock valued at $25,831,000 after buying an additional 9,994 shares in the last quarter. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its stake in shares of Eli Lilly and Company by 34.3% in the 3rd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 2,858 shares of the company’s stock worth $2,532,000 after acquiring an additional 730 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several research reports. Wolfe Research began coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Wells Fargo & Company lowered their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Trading Up 0.9 %

Eli Lilly and Company stock opened at $878.09 on Friday. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a market cap of $833.59 billion, a P/E ratio of 74.99, a P/E/G ratio of 1.87 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50-day simple moving average of $789.87 and a two-hundred day simple moving average of $843.55.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. Analysts predict that Eli Lilly and Company will post 23.33 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.68%. Eli Lilly and Company’s payout ratio is 44.41%.

Eli Lilly and Company declared that its board has authorized a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.